The Results Are In: S+ by ResMed Users See Improvement in The Amount and Quality of Their Sleep

Data Shows That Among Poor Sleepers, Improved Sleep Knowledge Leads to Improved Sleep

SAN DIEGO, June 10, 2015 /PRNewswire/ -- New results from S+ by ResMed, the world's first non-contact sleep system, show that after only one week of use, more than two-thirds of users with below-average sleep scores saw significant improvement. ResMed (NYSE: RMD), the global leader in the treatment of sleep-disordered breathing and other respiratory conditions, announced that 67% of such S+ users saw improved sleep times after the first week of use – an average of 31 minutes of extra sleep per night – once they began using the device.

Released in October 2014, the S+ by ResMed is a personalized sleep solution using patented bio-motion sensors to monitor and analyze sleep. The device measures an individual's sleep stages and sleeping environment to deliver daily sleep scores and provide personalized feedback to help improve sleep. It uses ResMed's proprietary touchless monitoring technology, allowing users to simply turn on the device at bedtime and eliminate the need to wear a watch, wristband, or other sensor.

"More than 50% of Americans have trouble sleeping and many of them don't understand why," said Colin Lawlor, vice president, ResMed consumer business. "These results show that gaining a better understanding of sleep patterns is an important first step toward improving the quality of your sleep. The S+ provides that insight, whether it suggests that you take an evening walk or notices that early morning light may be impacting your sleep."

S+ monitors sleeping patterns from the users' bedside table, sending real-time sleep information to the S+ by ResMed app, available on iOS- or Android-enabled devices. The data is then laid out on easy-to-read charts and graphs that help set users on a path toward better sleep. The app also includes several additional features that help users fall to sleep with greater ease.

ResMed has more than 25 years of experience in the sleep industry. S+ provides personalized feedback, finely tuned from extensive research and studies informed by more than two million hours of actual sleep data. Users can also download a personalized sleep report that can be shared with a physician to facilitate a discussion on their sleep trends.

For more information about the results of the study, derived from a sample of all S+ users as of 03/19/2015, or to learn more about the S+ by ResMed, visit S+ is available online and at retail stores including Apple, Bed Bath & Beyond and Best Buy. Consumers can purchase the device for $99.99 for a limited time from select retailers.

ResMed is committed to protecting the privacy and security of personally identifiable information. Sleep data collected for this report was analyzed in the aggregate. For more information on ResMed's S+ privacy policy, visit

About ResMed
The global team at ResMed (NYSE:RMD) is united in its commitment to changing lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other key chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit or follow @resmed on Twitter.


For News Media

For Investors

Alison Graves

Agnes Lee

Director, Corporate Communications

Senior Director, Investor Relations

O: 858-836-6789

O: 858-836-5971


ResMed Inc. logo.

Logo -


To view the original version on PR Newswire, visit:

SOURCE ResMed Inc.